Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Carter

Showing results (131-140 of 137) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 137 results.
Gynecologic Oncology|March 17, 2019
Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in AustraliaLouiza S Velentzis, Megan A Smith, Kate T Simms, et al.
Breast Cancer Research : BCR|November 13, 2016
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 womenTimothy R Rebbeck, Tara M Friebel, Nandita Mitra, et al.
British Journal of Cancer|June 20, 2019
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriersFrank Qian, Matti A Rookus, Goska Leslie, et al.
Breast Cancer Research : BCR|May 1, 2015
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriersSophie Blein, Claire Bardel, Vincent Danjean, et al.
Nature Communications|April 17, 2019
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancerManuel A Ferreira, Eric R Gamazon, Fares Al-Ejeh, et al.
Genetic Epidemiology|March 3, 2020
Transcriptome-wide association study of breast cancer risk by estrogen-receptor statusHelian Feng, Alexander Gusev, Bogdan Pasaniuc, et al.
Gynecologic Oncology|May 6, 2015
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer, Antoinette Hollestelle, Frederieke H van der Baan, et al.
Pageof 14

Showing results (131-140 of 137) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 137 results.
Gynecologic Oncology|March 17, 2019
Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in AustraliaLouiza S Velentzis, Megan A Smith, Kate T Simms, et al.
Breast Cancer Research : BCR|November 13, 2016
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 womenTimothy R Rebbeck, Tara M Friebel, Nandita Mitra, et al.
British Journal of Cancer|June 20, 2019
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriersFrank Qian, Matti A Rookus, Goska Leslie, et al.
Breast Cancer Research : BCR|May 1, 2015
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriersSophie Blein, Claire Bardel, Vincent Danjean, et al.
Nature Communications|April 17, 2019
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancerManuel A Ferreira, Eric R Gamazon, Fares Al-Ejeh, et al.
Genetic Epidemiology|March 3, 2020
Transcriptome-wide association study of breast cancer risk by estrogen-receptor statusHelian Feng, Alexander Gusev, Bogdan Pasaniuc, et al.
Gynecologic Oncology|May 6, 2015
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer, Antoinette Hollestelle, Frederieke H van der Baan, et al.
Pageof 14